Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 2/20 | 0.59 |
| ▸ | BRAF | P15056 | 5/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 5/20 | 0.46 |
| ▸ | MAP4K2 | Q12851 | 5/20 | 0.46 |
| ▸ | CSK | P41240 | 5/20 | 0.46 |
| ▸ | MAP3K20 | Q9NYL2 | 4/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | RAF1 | P04049 | 3/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | LYN | P07948 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.44 |
| ▸ | ABL2 | P42684 | 2/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.44 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.44 |
| ▸ | ARAF | P10398 | 1/20 | 0.44 |
| ▸ | FES | P07332 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2282782 | 0.88 | DDR1 (0.78) | DDR1BRAFMAPK14MAP3K7MAP4K2 | |
| SCHEMBL26882862 | 0.86 | DDR1 (0.78) | DDR1BRAFMAPK14MAP3K7MAP4K2 | |
| SCHEMBL17208712 | 0.85 | BRAF (0.67) | DDR1BRAFMAPK14MAP3K7MAP4K2 | |
| SCHEMBL2278943 | 0.80 | DDR1 (0.65) | DDR1MAPK14MAP3K7MAP4K2CSK | |
| SCHEMBL26882821 | 0.79 | BRAF (0.55) | DDR1BRAFMAPK14MAP3K7MAP4K2 | |
| SCHEMBL17208708 | 0.78 | MAPK14 (0.65) | DDR1BRAFMAPK14MAP3K7MAP4K2 | |
| SCHEMBL17208707 | 0.77 | MAPT (0.47) | DDR1BRAFEGFRDDR2 | |
| SCHEMBL17208710 | 0.76 | MAP3K20 (0.64) | DDR1BRAFMAPK14MAP3K7MAP4K2 | |
| SCHEMBL14702344 | 0.76 | DDR1 (0.83) | DDR1BRAFMAPK14MAP3K7MAP4K2 | |
| SCHEMBL2283239 | 0.76 | DDR1 (0.74) | DDR1BRAFMAPK14MAP3K7MAP4K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826365-B2 | Type II raf kinase inhibitors | BRAF, RAF1, ARAF | DDR1 1181/4885BRAF 1/4885MAPK14 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.